Tom Stargardt
Tom Stargardt
Professor for Health Care Management
Verified email at uni-hamburg.de - Homepage
TitleCited byYear
Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries
J Schreyögg, T Stargardt, O Tiemann, R Busse
Health Care Management Science 9 (3), 215-223, 2006
2492006
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches
AK Buck, K Herrmann, T Stargardt, T Dechow, BJ Krause, J Schreyögg
Journal of nuclear medicine technology 38 (1), 6-17, 2010
1972010
Management im Gesundheitswesen: Das Lehrbuch für Studium und Praxis
R Busse, J Schreyögg, T Stargardt
Springer-Verlag, 2017
190*2017
Defining the “Health Benefit Basket” in nine European countries
J Schreyögg, T Stargardt, M Velasco-Garrido, R Busse
The European Journal of Health Economics 6, 2-10, 2005
1032005
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
M Drummond, B Jönsson, F Rutten, T Stargardt
The European Journal of Health Economics 12 (3), 263-271, 2011
892011
Reforms in the Greek pharmaceutical market during the financial crisis
S Vandoros, T Stargardt
Health policy 109 (1), 1-6, 2013
872013
Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries
T Stargardt
Health economics 17 (S1), S9-S20, 2008
842008
Patient‐reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain
E Marrett, T Stargardt, P Mavros, CM Alexander
Diabetes, obesity and metabolism 11 (12), 1138-1144, 2009
762009
Availability of and Access to Orphan Drugs
CR Blankart, T Stargardt, J Schreyögg
Pharmacoeconomics 29 (1), 63-82, 2011
672011
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes
T Stargardt, L Gonder-Frederick, KJ Krobot, CM Alexander
Health Qual Life Outcomes 7, 91, 2009
602009
Impact of Cross-Reference Pricing on Pharmaceutical Prices: Manufacturers Pricing Strategies and Price Regulation
T Stargardt, J Schreyogg
Applied Health Economics and Health Policy 5 (4), 235-247, 2006
602006
Cost-effectiveness of hybrid PET/CT for staging of non–small cell lung cancer
J Schreyögg, J Weller, T Stargardt, K Herrmann, C Bluemel, T Dechow, ...
Journal of Nuclear Medicine 51 (11), 1668-1675, 2010
592010
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund
S Weinbrenner, HJ Assion, T Stargardt, R Busse, G Juckel, CA Gericke
Pharmacopsychiatry 42 (2), 66, 2009
502009
Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching
J Schreyögg, T Stargardt, O Tiemann
Health Economics 20 (1), 85-100, 2011
472011
The Trade‐Off between Costs and Outcomes: The Case of Acute Myocardial Infarction
J Schreyögg, T Stargardt
Health Services Research 45 (6p1), 1585-1601, 2010
462010
The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
T Stargardt
The European Journal of Health Economics 11 (3), 267-277, 2010
462010
Cost of illness and economic burden of chronic lymphocytic leukemia
CR Blankart, T Koch, R Linder, F Verheyen, J Schreyögg, T Stargardt
Orphanet journal of rare diseases 8 (1), 32, 2013
432013
Effect of Type of Insurance and Income on Waiting Time for Outpatient Care
K Roll, T Stargardt, J Schreyögg
The Geneva Papers on Risk and Insurance-Issues and Practice, 2012
382012
Determining the “Health Benefit Basket” of the statutory health insurance scheme in Germany
R Busse, T Stargardt, J Schreyögg
The European Journal of Health Economics 6, 30-36, 2005
362005
Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care
T Stargardt, S Weinbrenner, R Busse, G Juckel, CA Gericke
Journal of Mental Health Policy and Economics 11 (2), 89, 2008
302008
The system can't perform the operation now. Try again later.
Articles 1–20